Cost‐effectiveness analysis of CYP2C19 genotype‐guided antiplatelet therapy for patients with acute minor ischemic stroke and high‐risk transient ischemic attack in China

医学 西洛他唑 氯吡格雷 替卡格雷 阿司匹林 质量调整寿命年 CYP2C19型 轻微中风 内科学 冲程(发动机) 成本效益 心脏病学 风险分析(工程) 细胞色素P450 工程类 狭窄 机械工程 新陈代谢
作者
Zhuolin Zhang,Yuwen Bao,Yajie Gu,Mengdie Zhang,Xin Li
出处
期刊:British Journal of Clinical Pharmacology [Wiley]
卷期号:90 (2): 483-492 被引量:1
标识
DOI:10.1111/bcp.15921
摘要

Aims The study aimed to estimate the cost‐effectiveness of CYP2C19 genotype‐guided antiplatelet therapy using cilostazol and ticagrelor as an alternative to clopidogrel, compared to conventional antiplatelet therapy with clopidogrel and aspirin. Methods A 90‐day decision tree and 30‐year Markov model were employed to assess the costs and quality‐adjusted life years (QALYs) of personalized antiplatelet therapy for patients with minor ischemic stroke and high‐risk transient ischemic attack, compared to conventional antiplatelet therapy in the Chinese healthcare system. The primary outcome was the incremental cost‐effectiveness ratio (ICER). The data sources included clinical trials, published literature, official documents and local prices. One‐way sensitivity analysis and probabilistic sensitivity analysis were performed to confirm the robustness of the findings. Results The base‐case analysis indicated that the CYP2C19 genotype‐guided antiplatelet strategy was cost‐effective, and cilostazol group and ticagrelor group yielded an ICER of 3327.40 US dollars (USD)/QALY and 3426.92 USD/QALY, respectively, which were less than threshold. The one‐way sensitivity analysis showed the results were robust, where the most sensitive parameter was the disability distribution in the modified Rankin scale 3‐5. The probabilistic analysis showed that the CYP2C19 genotype‐guided antiplatelet therapy with either cilostazol or ticagrelor was 100% cost‐effective under the willingness‐to‐pay threshold. Conclusions CYP2C19 genotype‐guided antiplatelet therapy using cilostazol and ticagrelor as an alternative to clopidogrel appeared to be more cost‐effective than conventional antiplatelet therapy for acute minor ischemic stroke and high‐risk transient ischemic attack patients over 30 years in China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SYLH应助科研通管家采纳,获得10
刚刚
Ava应助科研通管家采纳,获得10
刚刚
刚刚
小马甲应助科研通管家采纳,获得10
刚刚
刚刚
我是老大应助科研通管家采纳,获得10
刚刚
1秒前
3秒前
4秒前
4秒前
hhh发布了新的文献求助10
5秒前
6秒前
凩飒给凩飒的求助进行了留言
7秒前
一程发布了新的文献求助10
7秒前
巴黎的防发布了新的文献求助10
8秒前
义气沉鱼发布了新的文献求助10
10秒前
Komorebi完成签到 ,获得积分10
11秒前
11秒前
搜集达人应助小红的忧伤采纳,获得10
12秒前
daying完成签到,获得积分10
14秒前
半糖糖完成签到,获得积分10
14秒前
15秒前
竹简发布了新的文献求助10
15秒前
16秒前
愤怒的小马完成签到,获得积分10
18秒前
半糖糖发布了新的文献求助10
19秒前
21秒前
Amanda发布了新的文献求助10
21秒前
秦文完成签到 ,获得积分10
25秒前
王WW发布了新的文献求助10
25秒前
淡定幻翠发布了新的文献求助10
28秒前
28秒前
29秒前
星辰大海应助白小超人采纳,获得10
30秒前
星辰大海应助Amanda采纳,获得10
30秒前
32秒前
32秒前
36秒前
桃之夭夭发布了新的文献求助10
38秒前
43秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3962475
求助须知:如何正确求助?哪些是违规求助? 3508497
关于积分的说明 11141410
捐赠科研通 3241254
什么是DOI,文献DOI怎么找? 1791445
邀请新用户注册赠送积分活动 872863
科研通“疑难数据库(出版商)”最低求助积分说明 803417